seasonal flu
Recently Published Documents


TOTAL DOCUMENTS

199
(FIVE YEARS 99)

H-INDEX

8
(FIVE YEARS 4)

Author(s):  
Indrani Roy

There is a strong coordinated effort by vaccination groups all over the world to put an end to the current crisis of COVID-19. The Mass vaccination first started in the UK on 8th December 2020 and soon afterward covered all of the globe. Now sufficient data are available to analyse and compare some results to explore many aftereffects of vaccination. Some influence variables on transmissions of the disease were discussed e.g., mass vaccination, lockdown and seasonality. To address seasonality, similarities between COVID-19 and seasonal Flu are discussed to gain useful insight. Like Flu, seasonality was shown to play a dominant role in transmissions of COVID-19 in the Eu-rope and US. In terms of mass vaccination, adverse reactions after vaccination received attention, as health and safety issues of the general public are of prime importance. Apart from direct side effects, the secondary effect of mass vaccination needs attention too. After the initiation of vaccination programme , almost all countries experienced a sudden surge of transmission and most countries had to impose strict lockdown measures. Many countries, those showed a low prevalence of the disease, suddenly showed a steep jump after the onset of mass vaccination. Some countries even followed a synchronized pattern between the rate of transmissions and the variation of vaccine doses; the pattern seemed distinct with the sudden steep rise/fall in vaccine doses (e.g., countries India, Indonesia among others). In that context, fast mutation of the virus and new variants after mass vaccination and possible mechanisms/consequences were discussed. Balanced discussion, critical and open analyses are desperately needed in the current crucial stage. Debating, questioning and criticism are always the foundation of good science and the main pillars to its progress. Following that objective, it is an effort to explore pragmatically, areas relating to the effectiveness of the COVID-19 vaccine and the exit strategy via the pathway of vaccination. Policymakers, academics, patients and common people will be greatly benefitted from such critical, transparent and balanced analyses.


2022 ◽  
Author(s):  
Csaba G. Toth

In the first year and a half of the pandemic, the excess mortality in Hungary was 28,400, which was 1,700 lower than the official statistics on COVID-19 deaths. This discrepancy can be partly explained by protective measures instated during the COVID-19 pandemic that decreased the intensity of the seasonal flu outbreak, which caused on average 3,000 deaths per year. Compared to the second wave of the COVID-19 pandemic, the third wave showed a reduction in the differences in excess mortality between age groups and regions. The excess mortality rate for people aged 75+ fell significantly in the third wave, partly due to the vaccination schedule and the absence of a normal flu season. For people aged 40-77, the excess mortality rate rose slightly in the third wave. Between regions, excess mortality was highest in Northern Hungary and Western Transdanubia, and much lower in Central Hungary, where the capital is located. The excess mortality rate for men was almost twice as high as that for women in almost all age groups.


2021 ◽  
Author(s):  
Nerea Martin Almazan ◽  
Afsar Rahbar ◽  
Marcus Carlsson ◽  
Tove Hoffman ◽  
Linda Kolstad ◽  
...  

Susceptibility to SARSCoV2 infections is highly variable, ranging from asymptomatic and mild infections in most, to deadly outcome in few. Here, we present evidence that antibodies induced by currently circulating influenza A H1N1 (flu) strains cross react with the most critical receptor binding motif of the SARSCoV2 spike protein that interacts with the ACE2 receptor. About 58 to 68% of blood donors in Stockholm had detectable antibodies to this cross-reactive peptide, NGVEGF, and seasonal flu vaccination trended to enhance binding of inhibitory antibodies to SARSCoV2. This peptide also activated CD8 T cells in 20% of healthy subjects. Eleven additional CD8 T cell peptides that cross react with flu and SARSCoV2 were identified that potentially protect against SARSCoV2 in 40 to 71% of individuals, depending on their HLA type.


2021 ◽  
Vol 15 (1) ◽  
pp. 28
Author(s):  
François Dufrasne

Baloxavir marboxil is a new drug developed in Japan by Shionogi to treat seasonal flu infection. This cap-dependent endonuclease inhibitor is a prodrug that releases the biologically active baloxavir acid. This new medicine has been marketed in Japan, the USA and Europe. It is well tolerated (more than 1% of the patients experienced diarrhea, bronchitis, nausea, nasopharyngitis, and headache), and both influenza A and B viruses are sensitive, although the B strain is more resistant due to variations in the amino acid residues in the binding site. The drug is now in post-marketing pharmacovigilance phase, and its interest will be especially re-evaluated in the future during the annual flu outbreaks. It has been also introduced in a recent clinical trial against COVID-19 with favipiravir.


Author(s):  
Emanuele Chittano Congedo ◽  
Maria Emilia Paladino ◽  
Michele Augusto Riva ◽  
Michael Belingheri

Healthcare students (HCSs) represent a target category for seasonal flu vaccination. This study aimed to examine adherence to flu vaccination campaigns from 2016 to 2019 among HCSs and to investigate knowledge and perception of and attitude toward influenza and flu vaccination. This cross-sectional study was conducted among the HCSs of a northern Italian university. Data on adherence, knowledge, perception, and attitude were investigated through an anonymous online self-administered questionnaire. The questionnaire was filled out by 352 out of 392 third-year HCSs (response rate = 90%). The main reason for refusal was the perception of influenza as non-threatening (24.4%), while self-protection was the main reason for adherence (87.5%). A univariate logistic regression analysis revealed some statistically significant associations with the adherence to the 2018–2019 campaign: being a nursing/midwifery student (OR: 4.14; 95% CI: 1.77–9.71) and agreeing with (OR: 19.28; 95% CI: 2.47–146.85) or being undecided (OR: 10.81; 95% CI: 1.33–88.27) about the obligation of vaccination in health facilities. The associations were also evaluated with a multiple logistic regression model. Despite the low vaccine uptake, good knowledge of the risks for HCSs and patients related to flu has emerged. Improving promotion strategies will be necessary to increase the adhesion of future healthcare workers.


2021 ◽  
Author(s):  
Addisu Wake

Abstract Introduction: Coronavirus disease 2019 (COVID-19) pandemic hasn’t been managed and controlled effectively, globally. The aim of this systematic review was to determine Pro-vaccination attitude and associated factors towards COVID-19 vaccine among healthcare workers (HCWs) and nonhealthcare workers (non-HCWs).Methods: Different databases such as PsycINFO, HINARI, Cochrane Library, PubMed, EMBASE, African Journals OnLine, Web of Science, Scopus, and Google Scholar for the related articles. Result: The levels of positive attitude towards COVID-19 vaccine among HCWs was ranged from 21% to 95%. Factors significantly associated with the attitude towards COVID-19 vaccine among HCWs were such as age, gender, race, work experience, home location, having no fear of injections, being a non-smoker, profession, presence of chronic illnesses, allergies, confidence in pharmaceutical companies, history of taking influenza vaccine, vaccine recommendation, perceived risk of new vaccines, perceived utility of vaccine, receiving a seasonal flu vaccination in the last 5 years, working in a private hospital, a high perceived pandemic risk index, low vaccine harm index, high pro-socialness index, being in close contact with a high-risk group, knowledge about the virus, confidence in and expectations about personal protective equipment and behaviors. The levels of positive attitude towards COVID-19 vaccine among non-HCWs was ranged from 21.4% to 91.99%. Factors associated with the attitude towards COVID-19 vaccine among non-HCWs were such as age, gender, educational level, occupation, marital status, residency, income, ethnicity, risk for severe course of COVID-19, direct contact with COVID-19 at work, being a health profession, being vaccinated against seasonal flu, perceived benefits, cues to actions, having previous history of vaccination, fear of passing on the disease to relatives, and the year of medical study, studying health-related courses, COVID-19 concern, adherence level to social distancing guidelines, history of chronic disease, being pregnancy, perceived vaccine safety, having more information about vaccine effectiveness, mandatory vaccination, being recommended to be vaccinated, lack of the confidence in the healthcare system to control epidemic, and believe in COVID-19 vaccines protection from COVID-19 infection. Conclusion: The level of positive attitude towards COVID-19 vaccine among both HCWs and non-HCWs were unfavorable and comparable. Globally, there is a need for a call for action to cease the time and crisis of this pandemic.


2021 ◽  
Vol 16 (11) ◽  
pp. 1934578X2110412
Author(s):  
Hui Liu ◽  
Wenxia Zhu ◽  
Yilin Wu ◽  
Caini Jiang ◽  
Lili Huo ◽  
...  

Before COVID-19, many viruses have infected humans, so what caused COVID-19 to be considered as a pandemic? COVID-19 belongs to the coronavirus family that includes severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS). This family has caused a large number of deaths all over the world. How risky is the novel coronavirus? People and their careers were disrupted, and many businesses all over the world are now closed. From here, it seems to us that this virus is something that can make people feel afraid. In this article, we will try to understand the severity of this virus, and then disclose the available ways to confront it and ways that might improve the ability to face it, either now or in the future. Upon comparing COVID-19 with seasonal flu, we have found that COVID-19 is about 10 times more deadly, although it is not the most infectious virus. In this review, we will discuss how healthy nutrition and lifestyle may help to prevent and treat diseases, and especially COVID-19. We will focus on how to follow healthy nutrition habits and lifestyles to stop the dangers of COVID-19.


2021 ◽  
Vol 15 (3) ◽  
pp. 127-132
Author(s):  
Sanem Eren Akarcan ◽  
Eda Karadağ Öncel ◽  
Tuba Tuncel ◽  
Emine Ece Özdoğru ◽  
Dilek Yılmaz Çiftdoğan

2021 ◽  
Author(s):  
Isaac Halstead ◽  
Ryan McKay ◽  
Gary Lewis

Vaccines are a powerful and relatively safe tool to protect against a range of serious diseases. Nonetheless, a sizeable minority of people express ‘vaccination hesitancy’. Accordingly, understanding the bases of this hesitancy represents a significant public health challenge. In the present study we sought to examine the role of Big Five personality traits and general intelligence as predictors of vaccination hesitancy, across two vaccination types, in a large (N= 9667) sample of UK adults drawn from the Understanding Society longitudinal household study. We found that lower general intelligence was associated with COVID-19 and seasonal flu vaccination hesitancy, and lower neuroticism was associated with COVID-19 vaccination hesitancy. Although the self-reported reasons for being vaccine hesitant indicated a range of factors were important to people, lower general intelligence was associated with virtually all of these reasons. In contrast, Big 5 personality traits showed more nuanced patterns of association. These findings provide important insights into vaccination hesitancy and help to reconcile some of the inconsistencies found in previous literature.


BMC Medicine ◽  
2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Thomas F. D. Mason ◽  
Matt Whitston ◽  
Jack Hodgson ◽  
Ruth E. Watkinson ◽  
Yiu-Shing Lau ◽  
...  

Abstract Background The BNT162b2 mRNA vaccine has been shown to be effective at preventing serious COVID-19 events in clinical trials. There is less evidence on effectiveness in real-world settings, especially for older people. Here, we aimed to estimate vaccine effectiveness in the context of the rapid NHS mass-vaccination programme in England, exploiting age-based vaccination eligibility thresholds to minimise and correct for selection bias. Methods We studied 170,226 individuals between the ages of 80 and 83 years from community settings outside care homes who received one dose of BNT162b2 mRNA between the 15 and 20 December 2020 and were scheduled a second dose 21 days later. We matched these vaccine recipients to slightly younger (aged 76–79 years) persons not yet eligible to receive the vaccine on gender, area of residence, area deprivation, health status, living arrangements, acute illness, and history of seasonal flu vaccination. We compared their rates of COVID-19 positivity and hospitalisation in the subsequent 45 days. We adjusted for the increasing concentration of COVID-19 positivity in the control population caused by the requirement to have no COVID-19 symptoms prior to vaccination. Results Emergency hospital admissions were 51.0% (95% confidence interval 19.9 to 69.5%) lower and positive COVID-19 tests were 55.2% (40.8 to 66.8%) lower for vaccinated individuals compared to matched controls 21 to 27 days after first vaccination. Emergency admissions were 75.6% (52.8 to 87.6%) lower, and positive COVID-19 tests were 70.1% (55.1 to 80.1%) lower 35 to 41 days after first vaccination when 79% of participants had received a second dose within 26 days of their first dose. Conclusions Receipt of the BNT162b2 mRNA vaccine is effective at reducing COVID-19 hospitalisations and infections. The nationwide vaccination of older adults in England with the BNT162b2 mRNA vaccine reduced the burden of COVID-19.


Sign in / Sign up

Export Citation Format

Share Document